Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Cash & Current Investments (2021 - 2025)

Historic Cash & Current Investments for ARS Pharmaceuticals (SPRY) over the last 5 years, with Q3 2025 value amounting to $288.2 million.

  • ARS Pharmaceuticals' Cash & Current Investments rose 4084.81% to $288.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $288.2 million, marking a year-over-year increase of 4084.81%. This contributed to the annual value of $314.0 million for FY2024, which is 3751.18% up from last year.
  • Per ARS Pharmaceuticals' latest filing, its Cash & Current Investments stood at $288.2 million for Q3 2025, which was up 4084.81% from $240.1 million recorded in Q2 2025.
  • ARS Pharmaceuticals' 5-year Cash & Current Investments high stood at $374.2 million for Q1 2021, and its period low was $60.1 million during Q4 2021.
  • For the 5-year period, ARS Pharmaceuticals' Cash & Current Investments averaged around $257.9 million, with its median value being $258.0 million (2022).
  • The largest annual percentage gain for ARS Pharmaceuticals' Cash & Current Investments in the last 5 years was 35682.2% (2022), contrasted with its biggest fall of 3216.37% (2022).
  • ARS Pharmaceuticals' Cash & Current Investments (Quarter) stood at $60.1 million in 2021, then soared by 356.82% to $274.4 million in 2022, then dropped by 16.77% to $228.4 million in 2023, then surged by 37.51% to $314.0 million in 2024, then fell by 8.22% to $288.2 million in 2025.
  • Its last three reported values are $288.2 million in Q3 2025, $240.1 million for Q2 2025, and $275.7 million during Q1 2025.